Search for Terms or Answers
Search for Terms or Answers
Results for “psoriatic arthritis”
Jack Cush, MD · Aug 22, 2024
Psoriatic arthritis (PsA) is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched, largely using claims data or retrospective data sets.
Jack Cush, MD · Jan 15, 2026
Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints. Why the disease progresses was assessed by researchers from the Universität…
Antoni Chan, MD, PhD · Jul 1, 2025
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.
Feb 10, 2026
Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, on two talks: "Why Do Plain X-Rays in Psoriatic Arthritis" by Dr. Arthur Kavanaugh and "Paradoxical Psoriasis and Strange Reactions" by Dr. Joseph Merola.
Nelly Ziade · Jun 17, 2025
Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies highlighted progress in prediction strategies. Here's my review of three of them.
Richard Conway, MBBChBAO, PhD · Feb 10, 2025
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
EurekAlert! · Apr 2, 2025
New research from the University of Bath in the UK reveals delayed diagnosis and undertreatment of psoriatic arthritis often results in irreversible damage to joints.Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults –…
EurekAlert! · Jun 12, 2025
Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not select for poor prognosis. The aim therefore of the SPEED trial (Severe Psoriatic arthritis – Early intervEntion to control Disease) – which was…
Jack Cush, MD · Dec 2, 2025
A substantial number of patients with psoriatic arthritis (PsA), have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: complex-to-manage PsA and treatment-refractory PsA.
jjcush · Mar 23, 2017
A comprehensive review of psoriatic arthritis (PsA) was published this week in the NEJM, authored by leaders in the field, Drs. Ritchlin, Colbert and Gladman.High points from their review inlcuded:Psoriasis (Pso) arthritis develops in up to 30% of patients with psoriasis Pso and PsA is…
Jiha Lee, MD · Jun 4, 2026
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Antoni Chan MD (Prof) · Jun 3, 2026
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026
Jun 5, 2026
Dr. Peter Nash reports on studies addressing the transition from PSO to PsA at EULAR 2026 in London.
MedPage Today · Jul 8, 2025
Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated.
jjcush · Mar 31, 2016
Researchers at the University of Toronto have prospectively studied a cohort of 464 psoriasis patients without a diagnosis of arthritis and followed them over 8 years to estimate the incidence and frequency of psoriatic arthritis (PsA). During the 8 years of follow-up, 51 patients…
jjcush · Jun 21, 2015
Estimates on the prevalence of psoriatic arthritis among psoriasis patients has varied widely, ranging from 5-40%. A systematic review of the literature shows that prevalence of undiagnosed PsA was 15.5% when all studies were considered and 10.1% when only epidemiological studies were…
Antoni Chan, MD, PhD · Jun 12, 2024
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
Antoni Chan, MD, PhD · Jun 11, 2025
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.
Jack Cush, MD · Mar 25, 2024
A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed within in less than 12 weeks) had the best clinical outcomes. Early PsA cohort included 708 consecutive PsA patients categorized by treatment delay (time…
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
